Neuronetics reports annual meeting results

Neuronetics , Inc. (NASDAQ:STIM), a medical technology company currently valued at $261 million, announced the results of its Annual Meeting of Stockholders that took place on May 22, 2025. The company, which has seen its stock surge over 312% in the past six months, held a meeting with substantial turnout, with over 81% of eligible shares represented, affirming a quorum. According to InvestingPro analysis, the company’s stock currently appears overvalued based on its Fair Value calculations, though analysts maintain optimistic sales growth forecasts for the current year.

The stockholders elected all nominees for director to serve one-year terms until the next annual meeting in 2026. The votes for each nominee were as follows: Avinash N. Amin, M.D. received 37,672,404 votes for and 45,557 withheld; Robert A. Cascella had 36,984,585 votes for and 733,376 withheld, and similar majorities were observed for the remaining candidates, all accompanied by 15,845,714 broker non-votes. With a current ratio of 2.44, the company maintains strong liquidity, though InvestingPro data reveals it remains unprofitable over the last twelve months with an EBITDA of -$35.78 million.

Additionally, the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with an overwhelming 53,498,731 votes for the proposal.

The stockholders also approved, on a non-binding advisory basis, the compensation of the company’s principal executive officer and two other most highly compensated executive officers for 2024, with 36,970,048 votes for the proposal.

A proposal to amend the company’s certificate of incorporation and bylaws to eliminate supermajority voting requirements was not approved, receiving 11,685,491 votes for and 25,644,606 votes against the proposal.

The results of the annual meeting are based on the information provided in a recent SEC filing by Neuronetics, Inc. This announcement is in compliance with the Securities Exchange Act of 1934, as confirmed by the company’s Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary, W. Andrew Macan.

In other recent news, Neuronetics Inc. reported its first-quarter 2025 earnings, revealing a net loss of $0.21 per share, missing analyst expectations of a $0.19 loss per share. Despite the earnings miss, the company achieved a significant revenue increase of 84% year-over-year, reaching $32 million, surpassing forecasts of $29.07 million. This revenue growth was primarily driven by the integration of Greenbrook and expansion into adolescent TMS treatments. The integration of Greenbrook has achieved 95% of the anticipated synergies, contributing positively to the revenue figures. Neuronetics has provided full-year revenue guidance of $149-$155 million, with expectations of achieving a gross margin of approximately 55%. The company aims for cash flow positivity by the third quarter of 2025, driven by initiatives such as the rollout of SPRAVATO and the buy and bill model. Analysts from firms like Piper Sandler and Canaccord Genuity have noted the company’s strategic focus on expanding its Better Mental Health Provider program and optimizing its clinic network. Neuronetics’ continued focus on operational improvements and strategic priorities is expected to support its path to financial stability.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.